March 5th 2024
Identifying KPIs, benchmarks, key data points, and an actionable plan are all keys to accelerating study start-up cycles.
February 22nd 2024
Though artificial intelligence has yet to achieve its full potential, meaningful strides are still being made across the drug discovery funnel.
July 14th 2023
The addition of NEXT Oncology investigators expands Proxima CRO’s Phase I clinical trials network.
September 7th 2022
The struggle to translate promising movements in R&D.
August 12th 2022
Best practices for assessing publications.
Impact of FDA Project FrontRunner on Oncology Drug Development
Webinar Date/Time: Tuesday, December 10th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET
Accelerating Early-Phase Oncology Development with IQVIA Biotech Australia
Webinar Date/Time: Tuesday, May 21st, 2024 at 2pm PDT | 5pm EDT | 11pm CEST
How Statistical Modeling and Simulation is Supporting Drug Development
Webinar Date/Time: Wednesday, November 15th, 2023 at 11am EST | 8am PST | 4pm GMT | 5pm CET
Mastering the Logistics of Remote Visits in Global Decentralized Clinical Trials
Webinar Date/Time: Tue, Nov 14, 2023 11:00 AM EST
Righting the Ship in 2024 and Beyond: Navigating the First Extended Workforce Recession in the History of the Life Sciences Industry
Webinar Date/Time: Tue, Tue, Nov 28, 2023 11:00 AM EST
How can Phase I data from Western medicine accelerate drug development in China and Japan? The Science and Practice of Ethnobridging
Webinar Date/Time: Wed, May 10, 2023 11:00 AM EDT
Accelerate Clinical Trial Success with Genomics Experts
Webinar Date/Time: Thu, Mar 2, 2023 1:00 PM EST
R&D Using the Metaverse and Digital Twins
How the digital environment can transform drug development space.
With Project Optimus, Success Favors the Prepared
Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.
Program Aims to Tap Africa's Potential in Pharmacometrics
Rik de Greef, senior vice president of global quantitative science services at Certara discusses the organization's training initiatives in Africa.
Understanding FDA’s Perspective on Precision Dosing
Continued embrace of precision dosing will reduce costs and optimize clinical outcomes.
Moving Toward the Pharmaceutical Industry of the Future with Translational Medicine
Gabi Hanna, MD highlights the need for an effective therapy for acute pancreatitis.
Radiomics: What It is and What It Can Do for Clinical Trials
Radiomics can help life sciences companies realize the full value of their imaging pipelines.
The Future of Clinical Diagnostics
Pharmaceutical industry trends will directly impact the clinical diagnostic world, resulting in a more integrated therapeutic strategy.
The Thorough Phase I ECG
The rapid emergence and global acceptance of new regulatory guidance has thrust cardiac safety to the forefront of new drug development during recent years. This is because the cardiac safety effects of new drugs is the most common cause of drug withdrawal from the market, or delays and a lack of regulatory approval for marketing. The resulting ECG Global Regulatory Imperative creates issues and offers opportunities for new drug developers striving for Best Practices in this important area.